Who makes PF-08046049?

PF-08046049 is developed by Pfizer Inc..

What is the generic name of PF-08046049?

pf-08046049 is the generic (nonproprietary) name of PF-08046049.

Last reviewed 2026-04-20 · How we verify

PF-08046049 (pf-08046049)

Pfizer Inc. · Phase 1 active Quality 0/100

At a glance

Generic name	pf-08046049
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-08046049 CI brief — competitive landscape report
PF-08046049 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI